Interplay between cardiac transcription factors and non-coding RNAs in predisposing to atrial fibrillation

Alexander T. Mikhailov¹, Mario Torrado¹

¹ Institute of Health Sciences University of A Coruña, A Coruña, Spain

Abstract
There is growing evidence that putative gene regulatory networks including cardio-enriched transcription factors, such as PITX2, TBX5, ZFHX3, and SHOX2, and their effector/target genes along with downstream non-coding RNAs can play a potentially important role in the process of adaptive and maladaptive atrial rhythm remodeling. In turn, expression of atrial fibrillation-associated transcription factors is under the control of upstream regulatory non-coding RNAs. This review broadly explores gene regulatory mechanisms associated with susceptibility to atrial fibrillation—with key examples from both animal models and patients—within the context of both cardiac transcription factors and non-coding RNAs. These two systems appear to have multiple levels of cross-regulation and act coordinately to achieve effective control of atrial rhythm effector gene expression. Perturbations of a dynamic expression balance between transcription factors and corresponding non-coding RNAs can provoke the development or promote the progression of atrial fibrillation. We also outline deficiencies in current models and discuss ongoing studies to clarify remaining mechanistic questions. An understanding of the function of transcription factors and non-coding RNAs in gene regulatory networks associated with atrial fibrillation risk will enable the development of innovative therapeutic strategies.

Keywords
Atrial fibrillation; Gene regulatory networks; Transcription factors; Non-coding RNAs; Atrial myocardium
Introduction

Atrial fibrillation (AF) is the most common sustained arrhythmia in current clinical practice. There are different predisposing risk factors and conditions for the development of AF, but patients diagnosed with asymptomatic non-familiar AF do not have any traditional risk factors. Proarrhythogenic molecular remodeling, broadly defined as any change in atrial gene regulation that promotes atrial conduction disturbances, is potentially crucial for unraveling a sudden-onset of AF [1].

There is growing evidence that putative gene regulatory networks (GRNs) including cardio-enriched transcription factors (TFs) and their target genes can play a potentially important role in the process of adaptive and maladaptive atrial rhythm remodeling [2]. In addition, human genome-wide association studies (GWAS) have successfully identified chromosome loci of DNA variants associated with increasing risk for AF and their closest genes including those coding for cardio-enriched TFs (reviewed in [3, 4, 5, 6]). Recently, a number of studies have demonstrated that cardiac GRNs are under the control of interleaved networks of regulatory non-coding RNAs (ncRNAs), which include microRNAs (miRNAs) and long noncoding RNAs (lncRNAs). Mature miR transcripts (approximately 22-nucleotide long) act as inhibitors of target gene expression by either promoting mRNA degradation or suppressing translation. In this context, lncRNAs (more than 200 nucleotides long) can either activate or suppress gene expression by regulating chromatin conformation and TF binding or through sequestering miRNAs from their target mRNAs. Contemporary research has revealed that ncRNAs are dysregulated in many forms of adult heart disease in both patients and animal models [7, 8]. In particular, it was evidenced that ncRNAs may form additional critical layers of the intricate modulator architecture for the control of atrial gene expression [9, 10, 11, 12, 13, 14, 15].

This review broadly explores the gene regulatory mechanisms associated with susceptibility to AF providing key examples within the context of both cardiac TFs and ncRNAs. These two systems appear to have multiple levels of cross-regulation and act coordinately to achieve effective control of atrial rhythm effector gene expression. Perturbations of expression balance between TFs and ncRNA networks can promote AF development. In this context, several lines of evidence indicate that the TF-miRNA blueprint for AF susceptibility is distinct from that associated with chronic AF [16, 17]. Accordingly, the aim of the present review is to summarize the current evidence on the role of the cardiac TF-ncRNA co-regulatory networks in predisposition to AF. Deciphering the interplay between cardiac TFs and ncRNAs will likely lead to a more translational approach for preventing and treating AF.

Sources of atrial ectopic beats triggering fibrillation

Spontaneous self-terminating episodes of AF are one of the most common heart rhythm disorders. Ectopic pacemaking activity (i.e., electrical impulse generation outside the sino-atrial node (SAN)) and re-entry of excitation wavefronts are considered the most probable mechanisms involved in AF development. There is a substantial body of research demonstrating that erratic atrial premature beats can trigger AF in the presence of a vulnerable substrate. Once initiated, AF itself can lead to the so-called electric remodeling of atrial myocardium, which promotes fibrillation maintenance [1].

Focal triggering sites of spontaneous AF can reside in various anatomical structures such as the left atrial (LA) appendage as well as LA myocardial muscle extensions (“sleeves”) located in the pulmonary veins (PVs) (Fig. 1). The PVs are characterized by a unique myofiber architecture and electric properties that can lead to the ectopic activity that triggers AF, and PV ablation is widely used to terminate AF [18].
Fig. 1. Atrial activation patterns and transcription factors involved in the development of atrial fibrillation. 

a Normal atrial activation during sinus rhythm (SR). The sinus node (SAN) located at the entrance of the right superior cava vein in the right atrium (RA) generates electrical impulses which are distributed within large areas (big wide arrows) of the RA and left atrium (LA) to create normal rhythm. RV and LV right and left ventricles.

b Atrial ectopic (non-SAN) rhythm activation. Ectopic pacemaking activity (semi-circular arrows) in the LA, pulmonary veins (PVs), or RA can trigger the development of atrial fibrillation (AF). Clinical studies have evidenced that more than 80% of the AF trigger impulses originate within PV muscular sleeves and LA muscles. NKX2.5, SRF, MEF2C, GATA-6, PITX2, TBX5, ZFHX3, and SHOX2 are the core cardiac TFs, which are thought to be responsible for initiation of AF. TFs implicated in susceptibility to AF by genetic and functional assays in animal models coupled with studies of samples from AF patients are marked in red, while those marked in gray have only sporadically been associated with an increased risk of AF. (Heart images taken from http://www.michiganmedicalreport.com/michigan_cardiology/details/241/podcast.aspx, modified)
Some clinical data suggest that the right atrium (RA) could also play a role in AF triggering [19]. However, the LA and RA have different susceptibilities toward developing arrhythmias: LA arrhythmias are more frequently observed [20]. Atrial mapping in patients shows that paroxysmal AF may originate in the RA in no more than 20–25% of cases [21, 22].

In adult mice as well as in humans, the LA and RA differ in their gene expression patterns [23, 24, 25]. In this sense, some cardio-enriched TFs and miRNAs [26, 27] involved in the development and progression of AF demonstrating left-right asymmetry in their expression in atrial myocardium. Within the scope of this review, the expression patterns of several of such TFs and miRNAs in the human left and right atria are schematically outlined in Fig. 2.

**Fig. 2.** Schematic representation of transcription factors and microRNAs expression signatures in human left and right atria. The color intensity is proportional to relative differences in expression levels of the gene in the RA vs LA; lightly gray denotes a relatively low while black denotes a relatively high expression. RA right atrium, LA left atrium. Respective references are shown in brackets.

In addition to interatrial ectopic pacemaking activities, pathophysiological cardiac conditions, such as heart failure, valvular heart disease, hypertrophic cardiomyopathy, acute myocardial infarction, and congenital heart disease, can lead to AF development. Intriguingly, it was recently found that accumulation of atrial adipose tissue is associated with AF [28]. Moreover, it was evidenced that human adult atrial epicardial cells differentiate into adipocytes [29] that, in turn, can contribute, under certain conditions [30], to the formation of AF substrate.
Transcription factors–microRNA co-regulation in atrial fibrillation

AF susceptibility is associated with rapid transcriptional remodeling of atrial myocardium. It is generally accepted that TFs and miRNAs jointly regulate target gene expression by either feed-forward or feedback mechanisms. However, the different roles of many TFs and miRNAs in the development of AF have been separately studied. In spite of such a mechanistic dissociation in the field of basic AF research, we will try to bring together the scattered findings on the atrial TF–miRNA circuits underlining AF susceptibility. The analysis of opposite correlations between TF and miRNA expression levels have allowed the identification of TF–miRNA regulatory circuits which are of particular interest in the context of atrial predisposition to AF development.

**PITX2/miRNA circuits**

PITX2 (pituitary homeobox 2 or paired-like homeodomain transcription factor 2), a member of the bicoid class of homeobox genes, is located within the human 4q25 AF-associated locus. In humans, the gene is transcribed into four distinct variants: PITX2A, PITX2B, PITX2C, and PITX2D. PITX2C, the predominant cardiac variant of the gene, is more highly expressed in the adult LA compared to RA [31, 32, 33]. PITX2 has been extensively studied, particularly its functions in heart development. It is widely recognized that PITX2C implicated in multiple pathways of cardiac left–right (L–R) asymmetry [34, 35] also regulates L–R atrial identity. The phenotype of PITX2C-deficient mice is characterized by RA isomerism with two SANs at both right and left regions of sinoatrial junction, each expressing the same panel of SAN-specific molecular markers [36]. Of note, pediatric patients with RA isomerism, usually with two SANs, are characterized by a high incidence of AF [37]. There is growing evidence suggesting that PITX2 plays a role in regulating gene expression as well as electrical, functional, and structural integrity in adult LA [38]. Of note, PITX2 and NKX2-5 control the development of LA myocardial “sleeves” in the PVs (see Fig. 1), the most frequent arrhythmogenic focus in patients with AF [39].

GWAS in humans revealed that genetic variants at chromosome 4q25 constitute the strongest locus associated with AF. Some of these 4q25 variants are located in the proximity of the PITX2 gene suggesting that modulations of PITX2 expression in atria are associated with susceptibility to AF development [40]. In this sense, CRISPR-Cas9-mediated editing of one of the AF-associated 4q25 variants proximal to PITX2 in human stem cell-derived cardiomyocytes significantly downregulates PITX2C expression. This downregulation is most likely due to alteration of the TFAP2a (transcription factor AP-2 alpha) binding site(s) at the risk variant region that leads to inactivation of a putative PITX2 enhancer [41].

Loss-of-function mutations in PITX2 have been shown to be associated with familiar AF [42]. In addition, functional studies show that the mutation in the 5’ untranslated region of the PITX2 gene, identified in probands with severe AF, leads to downregulation of this gene expression in atrial myocytes at both basal conditions and rapid pacing [43]. Data from animal models are well in line with these findings. In mice, PITX2 haploinsufficiency predisposes to pacing-induced AF indicating that reduced PITX2 levels promote an arrhythmogenic substrate as observed in different mouse models [31, 44, 45, 46]. In addition, unstressed adult PITX2 mutant mice manifest electrocardiographic signs of sinus node dysfunction (SND) which is frequently associated with AF development in humans [47]. In this regard, it should be noted that the abnormal electrophysiological substrate for SND is localized in the RA while the majority of triggers and substrates for AF originate in the LA (see Fig. 1). Similarly to what has been observed in mice, there is an association between LA PITX2 downregulation and increased atrial arrhythmogenicity in a rat experimental model of hypertension with spontaneous atrial arrhythmias [48]. In model
cell-based assays, PITX2 knockdown significantly decreases the expression level of the ZFHX3 TF which, in turn, may contribute to the occurrence of AF [49]. While experimental data from animal models of PITX2 knockdown do provide evidence that PITX2 deficiency can play a role in susceptibility to AF, the results of transcriptomic profiling of atrial myocardium from patients with AF are not yet conclusive. Particularly, increased [50], decreased [45, 51], or unaltered [33] PITX2C levels were detected in atrial biopsy specimens from AF patients. PITX2 modulates atrial resting membrane potential and alters the effectiveness of Na channel blockers; antiarrhythmic agents were found to be more effective in suppressing arrhythmias in atria with reduced PITX2C mRNA levels [52]. In humans, AF risk single-nucleotide polymorphisms (SNPs) are associated with increased PITX2 expression [53]. These findings, taken together with the above data, indicate that the direct correlation between PITX2 expression levels in the atrial myocardium and a multifactorial disorder like human AF remains elusive. (For more details, see the comment [54].)

PITX2 can contribute to regulation of atrial contractility and arrhythmogenesis through multiple pathways including a variety of ion channel, calcium handling, and gap junction proteins that are crucial for atrial pacemaker activity [38]. In addition, the analysis of cardiac expression of multiple miRNAs regulated by PITX2 in the heart has yielded some interesting results in relation to the mechanisms by which PITX2 may modulate several pathways leading to AF [2, 38]. PITX2 expression is co-localized with the expression of miR-17-92 and miR-106b-25 clusters and loss of PITX2 causes decreased expression of the corresponding miRNAs. Mice deficient in these miRNA clusters reveal characteristics similar to those of PITX2 mutant mice, including a high predisposition to induced AF and dysregulation of SHOX2 and TBX3 expression [55].

Interestingly, when miRNA expression levels were found to either increase or decline during AF development [12, 56], they were likewise found to be modulated by PITX2 as revealed in two distinct PITX2 loss-of-function murine models that recapitulate some aspects of the human AF. Remarkably, expression of miR-21, which negatively regulates PITX2 in atrial-derived cells [17], was downregulated in these mutant mice [46]. Of note, expression of miR-21 is upregulated in the LA of patients with long-term persistent AF as well as in a mouse model of spontaneous AF [12, 57, 58] and after short-term AF episodes in pigs; transfection of atrial cardiomyocytes with miR-21 mimic leads to PITX2 downregulation [17]. In human patients, plasma levels of miR-21 significantly increased after AF ablation [59]. Together, these results highlight a possible reciprocal regulation between PITX2 and miR-21 in various AF settings, although the actual mechanism by which they might form feed-forward/feedback loops to propagate their adverse effects on atrial myocardium is not well understood.

PITX2C was shown to negatively regulate the expression of miR-1 in the adult mouse LA [45]. When overexpressed in normal or infarcted rat hearts, miR-1 represses the expression of potassium channel subunits and connexins and thus provokes arrhythmogenesis [60]. In the porcine model of spontaneous self-terminating AF, induced ectopic tachyarrhythmia caused rapid downregulation of PITX2C which was inversely correlated with miR-1 upregulation in the LA of paced animals [17]. In contrast, expression of miR-1 is downregulated in patients with chronic persistent AF [61]. Several lines of experimental evidence suggest that PITX2 also negatively regulates miR-29a expression in atrial myocardium [46, 62]. Importantly, a significant increase in the expression levels of miR-29a was observed in both LA [57] and RA [63] appendages from patients with chronic AF compared to those from the sinus rhythm controls. The calcium voltage-gated channel subunit alpha1C (CACNA1C) gene, playing an essential role in cardiac arrhythmogenesis, was identified as a target gene of miR-29a in atrial myocytes [63]. In this sense, it seems reasonable to suggest that suppression of aberrant activity of miR-29a by PITX2 could ameliorate AF.
As in the case of miRNAs, IncRNAs could also be potent regulators of AF risk factors [64]. Recently, RNA sequencing of human LA/RA pairs identified an intergenic IncRNA named PITX2 adjacent noncoding RNA (PANCR). Expression of PANCR positively correlates with PITX2C levels in human LA biopsy samples and PANCR may act as a positive regulator of PITX2C: PANCR knockdown represses PITX2C expression and in this regard mimics the consequences of PITX2C inactivation on mRNA and miRNA expression in differentiated cardiomyocytes [65].

Together, the data illustrate multiple levels of PITX2 regulation, potentially requiring further investigations of any proposed causative association between PITX2 expression levels in the human adult atria and the first clinically observable manifestations of a transient irregularity of the atrial rhythm.

**TBX5/miRNA circuits**

*TBX5*, a member of the Brachyury T-box TF family, is widely expressed in the human heart, including the atria [66]. *TBX5* undergoes extensive alternative splicing, generating several transcript variants encoding protein isoforms with different properties [67, 68]. Alteration of *TBX5* levels affects the expression of hundreds of genes, including genes implicated in AF pathogenesis [69, 70, 71].

The involvement of *TBX5* in human AF development was suggested through the analysis of the *TBX5* gain-of-function mutation in a large family of patients with mild Holt–Oram syndrome (HOS) and paroxysmal AF [72, 73]. However, *TBX5* loss-of-function mutations were found to be associated with a predisposition to the onset of AF in a subset of HOS patients [74]. Moreover, the *TBX5* loss-of-function mutation which decreases *TBX5* transcriptional activity was detected in patients with “lone” AF [75], suggesting that *TBX5* haploinsufficiency could contribute to AF development. In this regard, it was recently found that *TBX5*-knockout human cardiomyocytes are characterized by marked pro-arrhythmic activity [71].

The results of a number of GWAS analyses have linked intronic sequence variants of the *TBX5* gene to PR interval prolongation which is a surrogate AF risk marker in patients [76]. This is in line with growing evidence showing a strong association between several SNPs in the *TBX5* gene and lone AF in patients [68, 77]. Recent cis-expression quantitative trait locus analysis suggests that altered *TBX5* expression in the human LA plays a role in AF susceptibility [6].

Additional evidence linking *TBX5* and AF has emerged from studies in murine models. In mice, adult-specific *TBX5* deletion causes the rapid onset of AF affecting the expression of calcium-handling and other AF-susceptibility genes in atrial cardiomyocytes. In addition, it was found that *TBX5* directly activates PITX2, while *TBX5* and PITX2 antagonistically regulate membrane effector genes. Most importantly, it has been demonstrated that PITX2 suppression reverses the pro-arrhythmic effects of *TBX5* knockdown suggesting that deficiency of both, *TBX5* and PITX2 could lead to the onset of AF, but through opposite mechanisms [78]. Interestingly, PITX2 itself regulates the expression of *TBX5* in cardiomyocytes [79], and PITX2 insufficiency leads to molecular and electrophysiological impairment of calcium homeostasis in the mouse LA mediated by Wnt signaling genes and miRNAs [46].
Some studies have shown that miRNAs can act as essential components in TBX5-signaling networks at AF, through either regulation of their expression by TBX5 or regulation of TBX5 itself. In mouse cardiac cells and zebrafish embryos, TBX5 was found to be able to regulate the expression of several miRNAs [80] and, in particular, miR-19 [81, 82]. MiR-19 expression levels are significantly increased in the LA of patients with paroxysmal AF [83]. In the mouse heart, miR-19 is transcribed as part of the miR-17-92 cluster which expression is positively regulated by PITX2. TBX5 is a target gene of both miR-10a and miR-10b [84]. Expression of miR-10b was found to be upregulated in LA biopsies from patients with chronic AF and valvular heart disease [27] and miR-10b plasma levels are decreased in AF patients after catheter ablation [85]. In the porcine model, short-lasting atrial tachyarrhythmia was associated with significant upregulation of both miR-10a and miR-10b coupled with decreased TBX5 expression in the LA of paced animals that may be permissive for AF development [17]. TBX5-dependent enhancer IncRNAs might also be functionally involved in TBX5 regulated gene expression in atrial myocytes. Particularly, it was found that RYR2-associated cis-element RNA (RACER), a TBX5-dependent IncRNA, is required for expression of ryanodine receptor 2 (RYR2), the major calcium release channel on the sarcoplasmic reticulum in cardiomyocytes. As a whole, more than two thousand TBX5-dependent ncRNAs were identified in the mouse atria by deep sequencing [86].

Together, all these data indicate that alterations in TBX5 expression levels in atrial myocardium may be a trigger for the production of the arrhythmogenic substrate.

**ZFHX3/miRNA circuits**

ZFHX3, the zinc finger homeobox 3 gene (formerly known as ATFB1), encodes a TF which was described as a transcriptional repressor for myogenic differentiation [87]. ZFHX3 is highly expressed in the adult mouse heart [88] and human stem cell-derived cardiomyoblasts [89]. ZFHX3 regulates transcription via direct interaction with predicted AT (adenine- and thymine-rich) motifs in the promoter region of target genes.

ZFHX3 located on the human chromosome 16q22 is one of the major AF susceptibility-conferring genes found by SNP scanning in Caucasian [90], European [91], Chinese [92], and Japanese [93] populations. Recently, gene-based association tests in AF patients linked single common genetic polymorphisms of the ZFHX3 gene with different AF clinical phenotypes (paroxysmal and persistent AF), LA remodeling and, in turn, with AF recurrence after ablation [94, 95].

The results coming from in vitro cell-based assays show that ZFHX3 can play an important role in AF predisposition and also support GWAS data on ZFHX3 involvement in the genesis of human AF. It was found that tachypacing leads to ZFHX3 downregulation in cultured atrial HL-1 myocytes. In turn, ZFHX3 knockdown in HL-1 myocytes contributes to upregulation of mediators of inflammatory signaling [96] and deregulation of calcium homeostasis underlying increased atrial arrhythmogenesis [49].

There is growing evidence that ZFHX3 molecular interactions with other AF-susceptibility genes, such as PITX2 and TBX5, can markedly increase AF risk. In particular, experiments with both heart-irrelevant cell lines [97] as well as HL-1 atria-derived cells [46] revealed that silencing of ZFHX3 expression significantly downregulates the expression of PITX2C. Conversely, overexpression of ZFHX3 increased PITX2C expression. Remarkably, ZFHX3 knockdown also significantly increased expression of TBX5 [97].
ZFHX3 was predicted to be a downstream target gene of miR-1 and contains two miR-1 binding sites at its 3'-untranslated region; cell transfections with miR-1 mimics significantly decreased expression of ZFHX3 at both mRNA and protein levels [97]. Reduced levels of miR-1 expression were found in human AF [61] suggesting this could lead to a certain degree of ZFHX3 and PITX2 upregulation in diseased atria, preventing, to some extent, further aggravation of AF.

**SHOX2/miRNA circuits**

SHOX2, the short stature homeobox 2 gene, encodes a TF which controls the development and function of SAN (the primary site for initiation and maintaining of the normal sinus rhythm) located in the adult RA (Fig. 1). The human SHOX2 encodes two alternatively spliced transcripts. In a cardiac developmental context, SHOX2 functions as a pro-pacemaker factor and antagonizes the NKX2-5 activity in the PV myocardium (see Fig. 1) that is well known for its arrhythmogenic capacities [98, 99]. Transcriptome analysis did not reveal any significant differences in SHOX2 expression levels between the LA and RA in sinus rhythm patients (see Fig. 2 and references therein).

Expression analysis revealed significantly reduced SHOX2 transcript levels in RA samples from patients with early-onset AF. In addition, the miR-92b-5p was identified as a putative negative regulator of SHOX2 expression in particular cohort of AF patients carrying a mutation in the 3’ untranslated region of the SHOX2 gene [100]. However, the authors of this work investigated RA tissue, while AF normally originates in the LA. In mouse models, it was shown that PITX2 which is highly expressed in the LA and PV myocardium negatively regulates SHOX2 directly [44] or indirectly through upregulation of the miR-17-92/106b-25 cluster, that in turn represses SHOX2. Additionally, it was found that SHOX2 upregulation in the fetal LA promotes LA ectopic automaticity [55]. It is therefore tempting to speculate that an imbalance between the expression dosages of PITX2 and SHOX2 in the LA and PV myocardium may lead to AF. In this context, it is likely that inhibitors of excessive expression of SHOX2 in the LA could help prevent AF development.

**Concluding remarks**

Results of human AF GWAS screenings coupled with data from conditional gene manipulations in mice and cell-based functional assays identify a set of TF-miRNA co-regulatory loops as putative disease modules orchestrating susceptibility to induced or spontaneous AF. These modules include PITX2, TBX5, ZFHX3, and SHOX2 TFs and their upstream and downstream miRNAs (Fig. 3). Previously, these TFs have either been implicated in cardiac development and differentiation or have been shown to be mutated in patients with different subtypes of AF. Notably, the association between these TFs is significant, implying not only a synergetic, but also a previously unrecognized opposite regulation of the expression of common downstream AF-associated genes [78]. Remarkably, there is a growing evidence suggesting that other cardiac TFs, such as NKX2-5, SRF, and GATA-6, may be associated with or responsible for early-onset human AF [16, 101, 102, 103].
Cardiac transcription factors and related microRNAs that are known or suggested to be involved in the initiation of AF. AF susceptibility, as functionally validated using in vitro and in vivo models, is associated with deregulated expression of transcription factors (PITX2, TBX5, ZFHX3, and SHOX2) and related miRNAs (miR-21, miR-19, miR-17-92, and miR-92b). Bold arrows (black/white) denote either up or down expression of the genes. The question mark represents a speculative assertion that SHOX2 upregulation in the LA or PV myocardium might promote ectopic automaticity. Whether miR-10a and miR-10b are directly involved in AF predisposition remains to be experimentally determined. Of note, the miR-17–92 miRNA cluster generates a single polycistronic primary transcript that yields six mature miRNAs: miR-17, miR-18a, miR-19a, miR-19b, miR-20a, and miR-92a [107]. LA left atrium, PVs pulmonary veins

Could studies of atrial-associated TF-miRNA modules identify novel therapeutic targets and help to develop novel treatment strategies for the primary prevention of AF development or AF recurrence? Within each described module, a dynamic expression balance between TFs and miRNAs may have a certain clinical relevance as it was found that a low activity of PITX2, TBX5, and, probably, ZFHX3 can lead to or be associated with irregular ectopic atrial activity. In the porcine model of transitory AF, short-term atrial pacing resulted in significant upregulation of miR-21 and miR-10a/b which was associated with the downregulation of their respective target TFs, PITX2, and TBX5 [17]. In this respect, antagoniR-induced knockdown of miR-21 and miR-10a/b might be a means to prevent recurrence of AF paroxysms. However, future studies directed at an in-depth understanding of the pathways regulated by atrial TF-miRNA circuits in various AF settings are necessary before translational treatment strategies can be considered.

Besides the role as putative therapeutic targets, the cardiac-enriched nc-RNAs discussed in the present review may be employed as prognostic and diagnostic biomarkers in AF. Indeed, it is increasingly recognized that circulating plasma miRNAs could be promising biomarkers for risk stratification in AF patients [12, 104]. In particular, plasma levels of two PITX2-associated miR partners, miR-1 and miR-21, are decreased in patients with sustained atrial tachycardia [105] and paroxysmal AF [59, 106], respectively. In contrast to miRNAs, the profiling of circulating IncRNAs is only starting to emerge as a putative biomarker tool for heart disease.
Funding information
This work was supported in part by funds from the Institute of Health Sciences (University of A Coruña, A Coruña, Spain) and by a grant (GRC 2013/061) from the Autonomic Government of Galicia, Spain.

Compliance with ethical standards

Conflict of interest
The authors declare that they have no conflicts of interest.

References


atrial myocytes from chronic atrial fibrillation patients enhancing $I_{Ks}$ and decreasing $I_{Ca,L}$.


53. Martin RI, Babaei MS, Choy MK, Owens WA, Chico TJ, Keenan D, Yonan N, Koren MS, Keavney BD (2015) Genetic variants associated with risk of atrial fibrillation regulate expression of PITX2, CAV1, MYOZ1, C9orf3 and FANCC. J Mol Cell Cardiol 85:207–214


